| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 150.868 | 207.184 | 315.420 | 369.047 | 499.294 |
| Total Income - EUR | - | - | - | - | - | 151.169 | 207.285 | 315.628 | 369.048 | 499.367 |
| Total Expenses - EUR | - | - | - | - | - | 115.165 | 143.221 | 198.865 | 246.818 | 314.343 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 36.005 | 64.064 | 116.763 | 122.230 | 185.024 |
| Net Profit/Loss - EUR | - | - | - | - | - | 32.480 | 59.805 | 111.832 | 119.515 | 172.290 |
| Employees | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Masepharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 0 | 0 | 0 | 35.930 |
| Current Assets | - | - | - | - | - | 39.776 | 92.883 | 138.397 | 172.399 | 230.882 |
| Inventories | - | - | - | - | - | 688 | 16.721 | 29.262 | 29.932 | 33.457 |
| Receivables | - | - | - | - | - | 11.340 | 32.316 | 33.883 | 137.051 | 190.267 |
| Cash | - | - | - | - | - | 27.748 | 43.846 | 75.252 | 5.416 | 7.158 |
| Shareholders Funds | - | - | - | - | - | 32.521 | 86.147 | 114.360 | 119.565 | 172.888 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 7.835 | 6.737 | 24.044 | 52.834 | 93.983 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Masepharm S.r.l.